Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice

Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and efficacy of the combination of CDKIs plus radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliano, Ambrogio, Prestifilippo, Angela, Cantale, Ornella, Ferini, Gianluca, Fisichella, Giacomo, Fontana, Paolo, Sciacca, Dorotea, Giuffrida, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247460/
https://www.ncbi.nlm.nih.gov/pubmed/34221963
http://dx.doi.org/10.3389/fonc.2021.643155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247460/
https://www.ncbi.nlm.nih.gov/pubmed/34221963
http://dx.doi.org/10.3389/fonc.2021.643155

Ejemplares similares